Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)

Trial Profile

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Dec 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 06 Dec 2016 Results from this and other five studies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 15 Nov 2016 Results of propensity score matching analysis from this and other trial published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top